

Reginald F Frye

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3277076/reginald-f-frye-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140
papers

4,787
citations

38
h-index

62
g-index

143
ext. papers

5,231
ext. citations

4.3
avg, IF

5.21
L-index

#	Paper	IF	Citations
140	Evaluating an interactive teaching approach with personal genotyping to provide pharmacy students with a knowledge base for clinical pharmacogenetics. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021 , 4, 343-351	1.4	
139	Intensive Care Unit Delirium in Surgical Patients Is Associated with Upregulation in Tryptophan Metabolism. <i>Pharmacotherapy</i> , 2020 , 40, 500-506	5.8	4
138	Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020 , 9, 678-685	4.5	5
137	Effect of pterostilbene on drug metabolizing enzyme activity. <i>Saudi Pharmaceutical Journal</i> , 2019 , 27, 406-412	4.4	9
136	Relative Bioavailability of Silybin A and Silybin B From 2 Multiconstituent Dietary Supplement Formulations Containing Milk Thistle Extract: A Single-dose Study. <i>Clinical Therapeutics</i> , 2018 , 40, 103-113.e1	3.5	9
135	Metabolomic association between venous thromboembolism in critically ill trauma patients and kynurenine pathway of tryptophan metabolism. <i>Thrombosis Research</i> , 2018 , 165, 6-13	8.2	5
134	Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018 , 315, E163-E173	6	34
133	A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. <i>Frontiers in Pharmacology</i> , 2018 , 9, 752	5.6	14
132	The effect of milk thistle (<i>Silybum marianum</i>) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes. <i>Chemico-Biological Interactions</i> , 2017 , 271, 24-29	5	9
131	Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 56-61	6.1	13
130	Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. <i>Journal of the American Heart Association</i> , 2017 , 7,	6	10
129	Pharmacogenomics competencies in pharmacy practice: A blueprint for change. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017 , 57, 120-125	1.7	39
128	Effect of Low-Furanocoumarin Hybrid Grapefruit Juice Consumption on Midazolam Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 305-311	2.9	3
127	Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol. <i>Metabolomics</i> , 2016 , 12, 1	4.7	11
126	A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. <i>Hypertension</i> , 2016 , 68, 621-9	8.5	18
125	Early thrombin formation capacity in trauma patients and association with venous thromboembolism. <i>Thrombosis Research</i> , 2016 , 147, 13-15	8.2	14
124	Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. <i>Metabolomics</i> , 2016 , 12, 1	4.7	7

123	Inhibitory effect of six herbal extracts on CYP2C8 enzyme activity in human liver microsomes. <i>Xenobiotica</i> , 2015 , 45, 406-12	2	10
122	Enzyme- and transporter-mediated beverage-drug interactions: An update on fruit juices and green tea. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 1313-31	2.9	27
121	Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015 , 4, 669-79	4.5	26
120	Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients. <i>Metabolic Syndrome and Related Disorders</i> , 2015 , 13, 195-202	2.6	17
119	The role of pharmacogenetics in the treatment of chronic hepatitis C infection. <i>Pharmacotherapy</i> , 2014 , 34, 185-201	5.8	9
118	A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical Sciences</i> , 2014 , 918, 219-228	3.2	10
117	The effects of milk thistle (<i>Silybum marianum</i>) on human cytochrome P450 activity. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 1611-6	4	36
116	Is diabetes mellitus-linked amino acid signature associated with β -blocker-induced impaired fasting glucose?. <i>Circulation: Cardiovascular Genetics</i> , 2014 , 7, 199-205		19
115	In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. <i>Pharmacotherapy</i> , 2014 , 34, 114-22	5.8	25
114	Pharmacokinetic properties of pure xanthenes in comparison to a mangosteen fruit extract in rats. <i>Planta Medica</i> , 2013 , 79, 646-53	3.1	30
113	Current clinical evidence on pioglitazone pharmacogenomics. <i>Frontiers in Pharmacology</i> , 2013 , 4, 147	5.6	16
112	Pharmacometabolomics reveals racial differences in response to atenolol treatment. <i>PLoS ONE</i> , 2013 , 8, e57639	3.7	59
111	Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects. <i>Metabolism: Clinical and Experimental</i> , 2012 , 61, 641-51	12.7	103
110	Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. <i>British Journal of Clinical Pharmacology</i> , 2012 , 74, 445-55	3.8	35
109	Pharmacokinetics of valerianic acid in rats after intravenous and oral administrations. <i>Planta Medica</i> , 2012 , 78, 575-81	3.1	11
108	A Preliminary Study on the Effects of Self-Reported Dietary Caffeine on Pain Experience and Postoperative Analgesia. <i>Journal of Caffeine Research</i> , 2012 , 2, 159-166		4
107	Nicotine as a factor in stress responsiveness among detoxified alcoholics. <i>Alcohol and Alcoholism</i> , 2011 , 46, 39-51	3.5	6
106	Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. <i>Pharmacotherapy</i> , 2011 , 31, 942-50	5.8	22

105	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1111-8	3.5	39
104	Pharmacokinetics of Emangostin in rats after intravenous and oral application. <i>Molecular Nutrition and Food Research</i> , 2011 , 55 Suppl 1, S67-74	5.9	60
103	Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. <i>Planta Medica</i> , 2011 , 77, 311-21	3.1	67
102	Absolute/relative bioavailability and metabolism of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (tetraenes) after intravenous and oral single doses to rats. <i>Planta Medica</i> , 2011 , 77, 1794-9 ¹	3.1	7
101	Inhibitory effects of commonly used herbal extracts on UDP-glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 1522-8	4	41
100	Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 714-20	2.9	14
99	Inhibitory effects of commonly used herbal extracts on UGT1A1 enzyme activity. <i>Xenobiotica</i> , 2010 , 40, 663-9	2	38
98	Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids. <i>Drug Metabolism and Disposition</i> , 2010 , 38, 270-5	4	35
97	Atenolol exposure and risk for development of adverse metabolic effects: a pilot study. <i>Pharmacotherapy</i> , 2010 , 30, 872-8	5.8	6
96	Validation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010 , 878, 497-501	3.2	9
95	Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009 , 330, 532-40	4.7	39
94	Pharmacokinetics and tissue distribution of dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides after oral administration in rats. <i>Planta Medica</i> , 2009 , 75, 1306-13	3.1	16
93	Toxicological and Pharmacokinetic Evaluation of Concomitant Intake of Grapefruit Juice and Simvastatin in Rats after Repeated Treatment over 28 Days. <i>Planta Medica</i> , 2009 , 75, 1196-202	3.1	7
92	ESRD impairs nonrenal clearance of fexofenadine but not midazolam. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 2269-76	12.7	96
91	Determination of visnagin in rat plasma by liquid chromatography with tandem mass spectrometry and its application to in vivo pharmacokinetic studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 653-6	3.2	5
90	A sensitive and specific liquid chromatography-tandem mass spectrometry method for the determination of intracellular and extracellular uric acid. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 2032-8	3.2	51
89	Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 65-70	3.2	45
88	Plasma Coenzyme Q10 Predicts Lipid-lowering Response to High-Dose Atorvastatin. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 289-97	4.9	15

87	Effect of the acute phase response induced by endotoxin administration on the expression and activity of UGT isoforms in rats. <i>Drug Metabolism Letters</i> , 2008 , 2, 248-55	2.1	5
86	Interpopulation variation frequency of human inosine 5Rmonophosphate dehydrogenase type II (IMPDH2) genetic polymorphisms. <i>Genetic Testing and Molecular Biomarkers</i> , 2008 , 12, 513-6		7
85	A summer research training program to foster PharmD studentsRinterest in research. <i>American Journal of Pharmaceutical Education</i> , 2008 , 72, 23	2.5	27
84	Determination of N-desethylamodiaquine by hydrophilic interaction liquid chromatography with tandem mass spectrometry: application to in vitro drug metabolism studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008 , 863, 129-34	3.2	13
83	Determination of mycophenolic acid glucuronide in microsomal incubations using high performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008 , 870, 251-4	3.2	9
82	Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008 , 871, 130-4	3.2	22
81	Vancomycin Disposition following Intraperitoneal Administration in Children Receiving Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2007 , 27, 79-85	2.8	24
80	Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. <i>British Journal of Clinical Pharmacology</i> , 2007 , 63, 477-87	3.8	19
79	Effect of valerian, valerian/hops extracts, and valerenic acid on glucuronidation in vitro. <i>Xenobiotica</i> , 2007 , 37, 113-23	2	15
78	Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 1299-307	2.9	13
77	Liver disease selectively modulates cytochrome P450--mediated metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 235-45	6.1	171
76	Validation of incorporating flurbiprofen into the Pittsburgh cocktail. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 257-63	6.1	40
75	Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. <i>International Journal of Artificial Organs</i> , 2005 , 28, 808-16	1.9	9
74	Cytochrome P-450 activity is differentially altered in severely injured patients. <i>Critical Care Medicine</i> , 2005 , 33, 541-6	1.4	30
73	Effect of age and postoperative time on cytochrome p450 enzyme activity following liver transplantation. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 666-73	2.9	16
72	The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2005 , 59, 70-9	3.8	43
71	Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction. <i>European Journal of Clinical Pharmacology</i> , 2005 , 61, 583-93	2.8	25
70	Pharmacokinetics of Intraperitoneal Cefepime in Automated Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2005 , 25, 380-386	2.8	18

69	The effect of isoniazid on CYP2E1- and CYP4A-mediated hydroxylation of arachidonic acid in the rat liver and kidney. <i>Drug Metabolism and Disposition</i> , 2004 , 32, 727-33	4	41
68	Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. <i>Drug Metabolism and Disposition</i> , 2004 , 32, 512-8	4	152
67	Stability of cefepime in icodextrin peritoneal dialysis solution. <i>Annals of Pharmacotherapy</i> , 2004 , 38, 2041-4		8
66	Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. <i>Clinical Chemistry</i> , 2004 , 50, 2392-5	5.5	27
65	Simplified method for determination of rosiglitazone in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004 , 803, 317-20	3.2	32
64	Determination of trimethoprim in low-volume human plasma by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004 , 807, 301-5	3.2	6
63	Effect of St John's wort on imatinib mesylate pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 323-9	6.1	154
62	Bioequivalence revisited: influence of age and sex on CYP enzymes. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 618-27	6.1	114
61	Probing the world of cytochrome P450 enzymes. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2004 , 4, 157-62		28
60	Influence of DHEA administration on 24-hour cortisol concentrations. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 96-9	1.7	27
59	Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. <i>Journal of Clinical Pharmacology</i> , 2003 , 43, 84-91	2.9	73
58	Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 178-91	6.1	48
57	Hepatic drug metabolism and transport in patients with kidney disease. <i>American Journal of Kidney Diseases</i> , 2003 , 42, 906-25	7.4	89
56	Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. <i>Intensive Care Medicine</i> , 2003 , 29, 980-984	14.5	122
55	Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. <i>European Journal of Clinical Pharmacology</i> , 2003 , 58, 791-4	2.8	46
54	Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 74, 555-68	6.1	6
53	Coordinated intrahepatic and extrahepatic regulation of cytochrome p4502D6 in healthy subjects and in patients after liver transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 456-67	6.1	17
52	Determination of 20-hydroxyeicosatetraenoic acid in microsomal incubates using high-performance liquid chromatography-mass spectrometry (HPLC-MS). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003 , 794, 363-72	3.2	14

51	Stereoselective determination of the CYP2C19 probe drug mephenytoin in human urine by gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003 , 783, 265-71	3.2	7
50	Stability of atropine sulfate prepared for mass chemical terrorism. <i>Journal of Toxicology: Clinical Toxicology</i> , 2003 , 41, 771-5		5
49	Sensitive liquid chromatographic method using fluorescence detection for the determination of estradiol 3- and 17-glucuronides in rat and human liver microsomal incubations: formation kinetics. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002 , 774, 33-8	3.2	36
48	Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53, 155-62	3.8	37
47	Rapid microtiter plate assay for determination of inulin in human plasma and dialysate. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2002 , 28, 209-15	3.5	7
46	Identification of omega hydroxy fatty acids in biological samples as their pentafluoropropyl derivatives by gas chromatography/mass spectrometry with positive and negative ion detection. <i>Rapid Communications in Mass Spectrometry</i> , 2002 , 16, 1411-5	2.2	5
45	Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 718-28	6.1	81
44	Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 481-6	1.7	12
43	Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. <i>Journal of Cardiac Failure</i> , 2002 , 8, 315-9	3.3	119
42	High-performance liquid chromatographic assay for acetaminophen glucuronide in human liver microsomes. <i>Biomedical Applications</i> , 2001 , 753, 303-8		36
41	Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. <i>Kidney International</i> , 2001 , 59, 295-303	9.9	15
40	Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. <i>European Journal of Pharmaceutical Sciences</i> , 2001 , 14, 47-52	5.1	45
39	Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. <i>American Journal of Kidney Diseases</i> , 2001 , 37, 766-76	7.4	30
38	Intravenous Vancomycin Pharmacokinetics in Automated Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2001 , 21, 378-385	2.8	42
37	Sensitive and specific high-performance liquid chromatographic assay for 4Rhydroxyflurbiprofen and flurbiprofen in human urine and plasma. <i>Biomedical Applications</i> , 2000 , 749, 119-25		31
36	Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. <i>Pharmacotherapy</i> , 2000 , 20, 182-90	5.8	53
35	Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. <i>Pharmacotherapy</i> , 2000 , 20, 635-43	5.8	34
34	Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study. <i>Pharmacotherapy</i> , 2000 , 20, 745-9	5.8	7

33	In vivo modulation of CYP enzymes by quinidine and rifampin. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 68, 401-11	6.1	72
32	Intermittent Intravenous Piperacillin Pharmacokinetics in Automated Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2000 , 20, 686-693	2.8	18
31	Sex Differences in the Pharmacokinetics of Dehydroepiandrosterone (DHEA) after Single- and Multiple-Dose Administration in Healthy Older Adults. <i>Journal of Clinical Pharmacology</i> , 2000 , 40, 596-605 ⁹	2.9	9
30	Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 1639-44	5.9	35
29	Effect of ceftazidime on systemic cytokine concentrations in rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 3217-9	5.9	29
28	Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2000 , 11, 1310-1316 ^{12.7}	12.7	41
27	Pharmacokinetics of Intermittent Intraperitoneal Cefazolin in Continuous Ambulatory Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 1999 , 19, 65-70	2.8	49
26	Determination of famotidine in human plasma and urine by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1999 , 732, 239-43		33
25	Comparison of iothalamate clearance methods for measuring GFR. <i>Pharmacotherapy</i> , 1999 , 19, 943-50	5.8	14
24	DHEA and DHEA-S: a review. <i>Journal of Clinical Pharmacology</i> , 1999 , 39, 327-48	2.9	370
23	Pharmacokinetics of intermittent intraperitoneal ceftazidime. <i>American Journal of Kidney Diseases</i> , 1999 , 33, 111-7	7.4	34
22	Effect of disulfiram-mediated CYP2E1 inhibition on the disposition of vesnarinone. <i>Journal of Clinical Pharmacology</i> , 1999 , 39, 1177-83	2.9	5
21	Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 63, 296-302	6.1	20
20	Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail. <i>British Journal of Clinical Pharmacology</i> , 1998 , 46, 215-9	3.8	42
19	Simultaneous determination of p-aminohippuric acid, acetyl-p-aminohippuric acid and iothalamate in human plasma and urine by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1998 , 716, 305-13		23
18	Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. <i>American Journal of Kidney Diseases</i> , 1998 , 31, 1019-27	7.4	84
17	Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations. <i>American Journal of Kidney Diseases</i> , 1998 , 32, 410-4	7.4	46
16	A Sensitive Method for the Simultaneous Determination of Caffeine and its Dimethylxanthine Metabolites in Human Plasma: Application to CYP1A2 Phenotyping. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1998 , 21, 1161-1171	1.3	12

15	Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. <i>Journal of Clinical Pharmacology</i> , 1998 , 38, 82-9	2.9	27
14	Evaluation of gentamicin pharmacokinetics and dosing protocols in 195 neonates. <i>American Journal of Health-System Pharmacy</i> , 1998 , 55, 2280-8	2.2	21
13	Debilitating reaction following the initial dose of tramadol. <i>Annals of Pharmacotherapy</i> , 1997 , 31, 1150-22.9		25
12	Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. <i>Drug Safety</i> , 1997 , 16, 205-31	5.1	68
11	Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 62, 365-76	6.1	206
10	Effects of liver disease on the disposition of the opioid antagonist nalmefene. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 61, 15-23	6.1	17
9	The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene. <i>Journal of Clinical Pharmacology</i> , 1996 , 36, 144-51	2.9	13
8	Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection. <i>Biomedical Applications</i> , 1996 , 677, 178-82		12
7	Pharmacokinetics of abecarnil in patients with renal insufficiency. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 520-8	6.1	5
6	Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1996 , 686, 291-6		49
5	The effect of age on the pharmacokinetics of the opioid antagonist nalmefene. <i>British Journal of Clinical Pharmacology</i> , 1996 , 42, 301-6	3.8	9
4	Effect of renal insufficiency on CYP activity.. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 155-155	6.1	6
3	Impaired 6-hydroxychlorzoxazone elimination in patients with renal insufficiency: Implication for pharmacogenetic studies.. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 168-168	6.1	1
2	Estimation of the hepatic extraction ratio of indocyanine green in swine. <i>Clinical Science</i> , 1993 , 84, 681-56.5		8
1	Sensitive high-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in plasma. <i>Biomedical Applications</i> , 1993 , 613, 127-31		12